 Emmaus Life Sciences Inc OTCQX:EMMA announced positive transfusion data from a post-hoc analysis of its Phase 3 study of Endari in patients with sickle cell disease. Endari is a prescription L-glutamine oral powder that is approved by the US Food and Drug Administration to reduce complications of sickle cell disease. 